Tectonic Therapeutic, Inc. Total Assets
Tectonic Therapeutic, Inc. total assets. Based on the latest financial reports, Tectonic Therapeutic, Inc. (TECX) holds total assets worth $237.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TECX company net worth for the company's overall valuation and market capitalisation.
Total Assets of Tectonic Therapeutic, Inc. (2016–2025)
Total assets of Tectonic Therapeutic, Inc. from 2016 to 2025. This chart illustrates how Tectonic Therapeutic, Inc.'s total assets have evolved over time, based on quarterly financial data. See Tectonic Therapeutic, Inc. (TECX) share price today for real-time trading data and today's change.
Tectonic Therapeutic, Inc. - Asset Composition Analysis
Tectonic Therapeutic, Inc. Total Assets Breakdown (December 2025)
Tectonic Therapeutic, Inc. total assets breakdown as of December 2025. Tectonic Therapeutic, Inc.'s total assets of $237.03 Million consist of 98.6% current assets and 1.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 97.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Tectonic Therapeutic, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TECX working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tectonic Therapeutic, Inc.'s current assets represent 98.6% of total assets in 2025, a decrease from 99.6% in 2016.
- Cash Position: Cash and equivalents constituted 97.2% of total assets in 2025, down from 99.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tectonic Therapeutic, Inc. Competitors by Total Assets
Key competitors of Tectonic Therapeutic, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Tectonic Therapeutic, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.29 | 25.60 | 9.29 |
| Quick Ratio | 22.29 | 25.60 | 9.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $220.73 Million | $279.49 Million | $188.86 Million |
Tectonic Therapeutic, Inc. - Advanced Valuation Insights
This section examines the relationship between Tectonic Therapeutic, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 1.52 |
| Asset Growth Rate (YoY) | 70.7% |
| Total Assets | $261.04 Million |
| Market Capitalization | $396.85 Million USD |
Valuation Analysis
Above Book Valuation: The market values Tectonic Therapeutic, Inc.'s assets above their book value (1.52x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Tectonic Therapeutic, Inc.'s assets grew by 70.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tectonic Therapeutic, Inc. (2016–2025)
The table below shows the annual total assets of Tectonic Therapeutic, Inc. from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $261.04 Million | +70.72% |
| 2024-12-31 | $152.91 Million | +288.09% |
| 2023-12-31 | $39.40 Million | -16.54% |
| 2022-12-31 | $47.21 Million | +43.59% |
| 2021-12-31 | $32.88 Million | -87.88% |
| 2020-12-31 | $271.23 Million | +35.27% |
| 2019-12-31 | $200.51 Million | +50.22% |
| 2018-12-31 | $133.48 Million | +1800.87% |
| 2017-12-31 | $7.02 Million | +30.04% |
| 2016-12-31 | $5.40 Million | -- |
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RX… Read more